GlassScriptPhysician profile
Candace R Chitsaz
NPI 1447270962
$2,303.10
in general payments reported to CMS, 2019-2025
23 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $360 · 2023: $640 · 2024: $428 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.13 | 2021-2025 | |
| Lilly USA, LLC | $243.36 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $203.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $148.92 | 2023-2025 | Proclaim, Eterna, Freestyle Libre 3 |
| Pfizer INC. | $145.30 | 2022-2025 | |
| Amgen INC. | $89.20 | 2023-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $44.78 | 2021-2023 | Ajovy |
| Glaxosmithkline, LLC. | $41.61 | 2021-2022 | |
| Antares Pharma, INC. | $38.93 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $37.31 | 2021-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.32 | 2024-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.36 | 2025 | Caplyta |
| Dexcom, INC. | $33.17 | 2022-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $31.41 | 2021-2025 | Trintellix |
| Amarin Pharma, INC. | $27.45 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26.80 | 2025 | |
| Merck Sharp & Dohme LLC | $25.64 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Eisai INC. | $16.86 | 2021 | |
| Medtronic, INC. | $16.21 | 2024 | Intellis Adaptivestim |
| Axonics, INC. | $15.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.98 | 2021 | |
| Currax Pharmaceuticals LLC | $13.62 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Chitsaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.